JP Patent

JP5465716B2 — Ｎｋ１受容体アンタゴニストとしての５−［５−［２−（３，５−ビス（トリフルオロメチル）フェニル）−２−メチルプロパノイルメチルアミノ］−４−（４−フルオロ−２−メチルフェニル）］−２−ピリジニル−２−アルキル−プロリンアミド

Assigned to Nerre Therapeutics Ltd · Expires 2014-04-09 · 12y expired

What this patent protects

Patent listed against elinzanetant.

Drugs covered by this patent

Patent Metadata

Patent number
JP5465716B2
Jurisdiction
JP
Classification
—
Expires
2014-04-09
Drug substance claim
No
Drug product claim
No
Assignee
Nerre Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.